Key Highlights: Implications: By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand ac...
Key Highlights: Implications: Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access. Dual T2D/weight...
